In this article, we will discuss Infigratinib (Dosage Overview). So, let’s get started.
Infigratinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Select patients for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with Infigratinib based on the presence of an FGFR2 fusion or rearrangement, as detected by an FDA-approved test.
The recommended dosage of Infigratinib is 125 mg (one 100 mg capsule and one 25 mg capsule) orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. Continue treatment until disease progression or unacceptable toxicity.
Instruct patients to take Infigratinib on an empty stomach at least 1 hour before or 2 hours after food, at approximately the same time each day. Instruct patients to swallow capsules whole with a glass of water. Advise patients to not crush, chew, or dissolve capsules.
If a dose of Infigratinib is missed by ≥4 hours or if vomiting occurs, instruct patients to resume the regular daily dose schedule for Infigratinib the next day.